Blurbs

Analysts Are Bullish on Top Healthcare Stocks: Cocrystal Pharma (COCP), IGM Biosciences (IGMS)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cocrystal Pharma (COCPResearch Report), IGM Biosciences (IGMSResearch Report) and Cidara Therapeutics (CDTXResearch Report) with bullish sentiments.

Cocrystal Pharma (COCP)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cocrystal Pharma, with a price target of $42.00. The company’s shares closed last Friday at $2.39, close to its 52-week low of $2.05.

According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of -31.0% and a 20.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Fresh Tracks Therapeutics, and Oncternal Therapeutics.

Cocrystal Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $23.50.

See today’s best-performing stocks on TipRanks >>

IGM Biosciences (IGMS)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on IGM Biosciences today and set a price target of $45.00. The company’s shares closed last Friday at $16.50, close to its 52-week low of $12.67.

According to TipRanks.com, Burns ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -22.7% and a 22.6% success rate. Burns covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Springworks Therapeutics, and Neoleukin Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for IGM Biosciences with a $35.14 average price target, implying a 102.5% upside from current levels. In a report issued on November 4, Stifel Nicolaus also maintained a Buy rating on the stock with a $50.00 price target.

Cidara Therapeutics (CDTX)

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Cidara Therapeutics today and set a price target of $6.00. The company’s shares closed last Friday at $0.56, close to its 52-week low of $0.40.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 4.0% and a 35.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Paratek Pharmaceuticals, and Aurinia Pharmaceuticals.

Currently, the analyst consensus on Cidara Therapeutics is a Strong Buy with an average price target of $5.00, implying a 763.7% upside from current levels. In a report issued on November 4, Needham also maintained a Buy rating on the stock with a $6.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on COCP:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More